Kornimate/medical-research-clean huggingface dataset:
effect of video-based stabilization exercises on pain, function, adherence, kinesiophobia & qol in nscbp patients

Conditions: Non Specific Chronic Low Back Pain; Exercise Therapy

Summary: this randomized controlled study aims to evaluate the effectiveness of a 6-week home-based stabilization exercise program in individuals with non-specific chronic low back pain. participants will be randomly assigned to two groups: one receiving exercise instruction via video-based content, and the other via a printed brochure with illustrated exercises. the effectiveness of the interventions will be assessed in terms of pain severity, functional status, exercise adherence, kinesiophobia, and quality of life.

this study investigates the effectiveness of a 6-week home-based core stabilization exercise program in individuals with non-specific chronic low back pain (nsclbp). the purpose is to compare two different delivery methods of the same exercise protocol: video-based versus illustrated brochure-based instructions. stabilization exercises are commonly used in nsclbp management; however, the mode of delivery in home settings can impact adherence and clinical outcomes. a total of 42 participants with nsclbp will be randomly assigned to either the video-based group or the brochure-based group. both groups will follow the same exercise content, frequency, and duration. outcomes will be assessed at baseline and after 6 weeks using standardized tools for pain (visual analog scale), functional status ( oswestry disability index), exercise adherence (exercise adherence rating scale), kinesiophobia (tampa scale), and quality of life (sf-36). the findings will be contribute to the optimization of home exercise strategies for chronic low back pain management.

Eligibility criteria:
inclusion criteria: clinical diagnosis of non-specific chronic low back pain lasting 3 months or more age 18 years or older score of 4 or higher on the roland-morris disability questionnaire voluntary agreement to participate in the study exclusion criteria: physiotherapy treatment for low back pain within the past 6 months pain radiating to the lower extremities pregnancy history of spinal surgery presence of central or peripheral nervous system pathology (e.g., stroke)

Keywords: chronic low back pain core exercise exercise adherence
brain imaging of rtms treatment for depression

Conditions: Major Depressive Disorder; Depression

Summary: the overarching goal of this research program is to elucidate causal and directional neural network- level abnormalities in depression, and how they are modulated by an individually-tailored, circuit-directed intervention. by using concurrent tms and fmri, the investigators can overcome a major limitation of neuroimaging - the inability to demonstrate causality. the investigators' findings will serve as a platform for future studies wherein tms treatment can be directly guided by the investigators' ability to image and causally manipulate specific neural networks. aim 1: to examine causal interactions between two major brain networks in depression. aim 2: to examine the impact of antidepressant tms on causal network abnormalities in depression. hypothesis 1: depressed subjects will show blunted responses, compared to healthy controls, in two targeted and interacting networks, using concurrent transcranial magnetic stimulation (tms) and functional magnetic resonance imaging (fmri). hypothesis 2: treatment of patients with high-frequency repetitive tms (rtms) will result in normalization of baseline network-level deficits, and be predicted by degree of baseline network abnormalities.

this study has a single primary outcome measure and other measures are exploratory. previous versions of this study record incorrectly listed some exploratory outcome measures as secondary.

Eligibility criteria:
inclusion criteria: * men and women, ages 18 to 50 * depression assessed through phone screen * must comprehend english well to ensure adequate comprehension of the fmri and tms instructions, and of clinical scales * has failed \>1 previous adequate antidepressant medication trials * right-handed * no current or history of neurological disorders * no seizure disorder or risk of seizures exclusion criteria: * any contraindication to being scanned in the 3t scanners at the lucas center or cni such as having a pacemaker or implanted device that has not been cleared for scanning at the lucas center or cni * any unstable medical condition, any significant cns neurological condition such as stroke, seizure, tumor, hemorrhage, multiple sclerosis, etc * current rtms treatment or prior treatment failure with rtms * current electroconvulsive therapy (ect) or prior treatment failure with ect * currently pregnant or breastfeeding
screw lengths in radius volar plates

Conditions: Radius; Fracture, Lower or Distal End; Tendon Injury - Upper Limb; Fracture Fixation, Internal

Summary: background fractures of the distal radius are among the most common. major complications, including irritation and rupture of the extensor tendons, may occur if epiphyseal screws of inappropriate length are used. questions/purposes the main objective of the present study was to determine whether the optimal epiphyseal screw length can be determined by reference to the diaphyseal screw length. methods forty ct scans were semi-automatically segmented. a 3d model of the volar plate was affixed to each distal radius with simulation. the maximum lengths of the diaphyseal screws, as well as the four distal epiphyseal screws, were measured. linear regression analysis was performed.


Eligibility criteria:
inclusion criteria: * all ct-scans available in our database exclusion criteria: * any pathology that could affect the radius morphology * refuse to participate

Keywords: bone trauma-fracture radius ct-scan internal fixation
effect of acetazolamide on optic nerve sheath diameter in laparoscopic donor nephrectomies

Conditions: Intracranial Pressure Increase

Summary: the purpose of the trial is to study the effect of acetazolamide administered via ryle's tube on optic nerve sheath diameter in laparoscopic live donor nephrectomy patients.

this study was done on 40 american society of anaesthesiologist(asa) i \& ii live donors of either sex in adult age group undergoing laparoscopic live donor nephrectomy. after getting approval from institutes ethical committee and written informed consent, donors were randomly allocated to either of two group. anaesthesia was induced with injection morphine 0.1 mg/kg, injection propofol 1-2 mg/kg and vecuronium 0.1 mg/kg. maintenance of anaesthesia was done with isoflurane and oxygen. after induction donors were placed into modified flank position with left side upward. donors in group a received acetazolamide 5 mg/kg via orogastric tube soon after the induction of anaesthesia. group s received saline as a placebo. investigator and subjects were blinded till the statistical analysis. optic nerve sheath diameter was measured six times during perioperative periods by using high frequency ultrasound probe. intra operative monitoring was done for heart rate, blood pressure, pulse oximetry(spo2), end tidal carbon dioxide(etco2), train of four(tof) and bi spectral index(bis). post operatively donors were reversed with injection neostigmine and glycopyrrolate. once return of spontaneous ventilation was well established and patient becomes conscious oriented trachea was extubated and donors were shifted to post anaesthetic care unit(pacu). postoperatively donors were monitored for heart rate, blood pressure, spo2, comfort score, visual analog score for incisional site pain and shoulder tip pain, and post operative nausea vomiting. rescue analgesia was given to patients having comfort score less than 6. after completion of study optic nerve sheath diameter, pain scores and comfort scores was compared between both groups.

Eligibility criteria:
inclusion criteria: * patients of either gender * 18-60 years of age * hemodynamically stable patients. exclusion criteria: * patient's refusal. * ocular defects/ wounds /previous ocular surgery. * h/o hypertension * patients having double renal arteries. * laparoscopic nephrectomies converted to open surgeries

Keywords: optic nerve sheath diameter acetazolamide
a research platform to screen healthcare workers- coordinated approach to pandemic trials of covid-19

Conditions: Healthcare Worker; Covid19

Summary: recent studies have shown that some individuals may be asymptomatic but continue to shed the covid-19 virus. these individuals may represent a population that can unknowingly transmit the virus. healthcare workers (hcw) may acquire covid-19 from the community or from possibly infected patients. it is important to gather data with respect to this to further understand the prevalence of asymptomatic carriage in individuals who work in research facilities, offices and clinical areas of hospitals and research facilities/institutes since this has important implications for infection control, as well as staff and patient safety. the purpose of this study is to test whether a proportion of these individuals may be asymptomatic shedders of the covid-19 virus.

healthcare workers of participating institutions who agree to be participants will: * fill out some information about participants into a database portal system. participants will have the ability to check their covid-19 test results via the portal. * have nasopharyngeal (np) swabs done for covid-19 testing. this can be done about once a week for up to 8 weeks (about 1-8 swabs total). * provide optional blood samples to look for covid-19 specific antibodies and/or proteins at the time of enrollment and after 8 weeks. * fill out questionnaires about participant exposures and travel history, occupation category, any symptoms in the past 21 days, whether they have provided any face-to-face care of a known covid-19 positive patients in past 14 days or if participants have any children at home who are less than 12 years of age. * fill out an optional questionnaire about their mental health * be contacted by telephone if participants are tested positive, to determine whether participants have symptoms of covid-19, and for the results of any follow-up covid-19 testing that may have been done.

Eligibility criteria:
inclusion criteria: * individuals who work within a food production, healthcare, research or clinical organization. * asymptomatic as per daily screening. * no contraindication to performing a np swab. exclusion criteria: * any individual with fever, respiratory or flu-like symptoms will not be eligible. symptom positive individuals who were not picked up at entry screening will be referred to their occupational health. specific symptoms include: * fever, chills or headache * new or worsening cough * shortness of breath, difficulty breathing, sore throat or difficulty swallowing * runny nose or stuffy nose without another cause (e.g. allergies) * nausea/vomiting, diarrhea, stomach pain * decrease/loss of taste or smell * unexplained fatigue, malaise, muscle aches * eye pain or pink eye in addition to those symptoms listed above, individuals should also be screened for symptoms as per their institutional requirements. * enrolled in a covid-related interventional study (eg. behavioural or drug study).
study investigating ntla-5001 in subjects with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this study will be conducted to evaluate the safety, tolerability, cellular kinetics (ck), activity, and pharmacodynamics (pd) of ntla-5001 in participants with acute myeloid leukemia (aml).

this 2-part first in human (fih) study is comprised of two open-label arms. it is a multi-center, phase 1/2a study evaluating the safety and activity of ntla-5001 in subjects with persistent or recurrent acute myeloid leukemia after first-line or later therapy.

Eligibility criteria:
inclusion criteria (abbreviated): * has aml as defined by world health organization * has detectable disease following first-line therapy * is ≥ 18 years of age. * carries the human leukocyte antigen-a0201 (hla-a\*02:01) allele. * has ecog performance status of 0 to 1. * has adequate absolute total lymphocyte count * has adequate cardiac, renal, and liver organ function exclusion criteria (abbreviated): * has received aml-directed therapy or immunomodulatory therapy within a specified window prior to study entry. * has received allogeneic hematopoietic cell transplant within 84 days, with ongoing gvhd, with recent dli, or on active immunosuppression. * has cns involvement by tumor. * has severe autoimmunity requiring immunomodulatory therapy. * has active disseminated intravascular coagulation (dic), bleeding or coagulopathy. * has leukocytosis ≥ 20,000 blasts/μl despite hydroxyurea or has rapidly progressive disease * has human immunodeficiency virus (hiv) infection, or any uncontrolled infection. * female subjects are pregnant or breastfeeding; or are of childbearing potential and are unwilling to use protocol specified method of contraception. * male subjects who have female partners of childbearing potential and are unwilling to use protocol specified method of contraception.

Keywords: ntla-5001 cell kinetics pharmacodynamics clustered regularly interspaced short palindromic repeats crispr aml acute myeloid leukemia tcr t cell therapy autologous leukemia neoplasms immune system diseases immunoproliferative disorders
reward and drug effects on mood and brain response

Conditions: Cannabis Use; Healthy

Summary: the goal of the study is to better understand the neural mechanisms underlying the rewarding, reinforcing properties of delta-9-tetrahydrocannabinol (thc), the main psychoactive ingredient in cannabis, among healthy young adults.


Eligibility criteria:
inclusion criteria: * must be able to give informed consent * age 18-25 at the time of signing the consent form * fluency in english * body mass index of 19-26 (normal/overweight but not obese due to limitations of mri) * negative urine drug screen (uds) for all substances except thc (thc allowed) * must be medically and neurologically healthy * must not be taking psychoactive medications that would interfere with dronabinol and/or interpretation of fmri data, including but not limited to the following classes of psychotropics: antidepressants, anxiolytics, sedative hypnotics, stimulants, antipsychotics, mood stabilizer * have used cannabis at least 10 times in their life, but report current and past lifetime cannabis use less than 7 days/week (daily) exclusion criteria: * any current medical condition requiring psychoactive/psychotropic medication or medication that would interact with dronabinol, interpretation of fmri data, and/or interfere with study procedures * current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/thc, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide.) * current axis-i diagnostic statistical manual-5 diagnosis (although mild and moderate cannabis use disorder (cud) and mild and moderate alcohol use disorder (aud) are allowed) * score \>3 on the prediction of alcohol withdrawal severity scale (pawss) for individuals with current aud * lifetime other lifetime substance use disorder (although lifetime severe cud and lifetime severe aud are allowed) * currently seeking or engaged in cud treatment or have desire to cut down or stop cannabis use. * in recovery or enrolled in treatment for any substance (including cannabis and alcohol) * lifetime psychosis, mania, attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, feeding and eating disorder, or post-traumatic stress disorder * score \>7 on the hamilton depression rating scale or score \>7 on the hamilton anxiety rating scale * less than a high school education * lack of fluency in english * night shift work * currently pregnant confirmed by urine pregnancy test or planning pregnancy or lactating (women) * unwilling/unable to sign informed consent document * inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia), as determined by self-report * left-handed * presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles) * positive uds for any drug except thc * positive breathalyzer for acute alcohol intoxication * heavy alcohol use (\>4 days week) in the past month * heavy nicotine use (\>20 cigarettes per week) in the past month

Keywords: thc adult
registro campania salute network on hypertension

Conditions: Hypertension; Heart Disease, Hypertensive

Summary: the registro campania salute network (rcsn) is a prospective registry aimed at improving the management of essential hypertension by integrating the activity of general practitioners (gps) with that of the hypertension specialist. it involves selected gps homogeneously allocated in the regional area, and the hypertension clinic of the federico ii university in naples, which served as co-ordinating centre. through the rcsn system it is possible to store clinical data detected at each visit between the peripheral units and the co-ordinating centre and to support scientific analysis of the dataset.

the patients will be followed over a period of twenty years and all clinical data will be recorded in order to investigate the role of hypertension and correlated disease on this patient population

Eligibility criteria:
inclusion criteria: -hypertension * 18 years old exclusion criteria: * refused to sign informed consent

Keywords: hypertension cvd
real-world effectiveness of high-dose tafamidis on neurologic disease progression in mixed-phenotype transthyretin amyloid cardiomyopathy

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Summary: this study will examine the clinical effectiveness of tafamidis in patients with mixed phenotype transthyretin amyloidosis using data that already exist in patients' medical records


Eligibility criteria:
inclusion criteria: * age ≥18 years at diagnosis. * diagnosed with attrv-cm or attrwt-cm, mixed phenotype. * treated with tafamidis, as vyndamax 61 mg (one 61-mg tafamidis capsule) orally once daily for ≥12 months or started on tafamidis 20 mg then switched to vyndamax 61 mg for ≥12 months * have had ≥1 pre- and ≥1 post-treatment neurologic assessments. exclusion criteria: * history of any organ transplant. * individuals who are non-ambulatory. * prior or current treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as vyndaqel 80 mg \[four 20-mg tafamidis meglumine capsules\] orally once daily or vyndamax 61 mg \[one 61-mg tafamidis capsule\] orally once daily. * peripheral neuropathy attributed to causes other than attr amyloidosis (eg, diabetes mellitus, b12 deficiency, hypothyroidism, shingles,lyme disease, hiv infection, secondary to injury, chronic kidney disease). * patient's data fails to pass data quality checks.
serum alpha-fetoprotein levels and response to direct antiviral therapy in patients with chronic hepatitis c

Conditions: Hepatitis C

Summary: alpha-fetoprotein levels on the response to direct antiviral therapy in patients with chronic hepatitis c

impact of serum alpha-fetoprotein levels on the response to direct antiviral therapy in egyptian patients with chronic hepatitis c

Eligibility criteria:
inclusion criteria: * hcv patients who will undergo treatment by direct acting antiviral agents. exclusion criteria: * patients with decompensated liver disease
decentering and relapse/recurrence in mbct for depression in adults

Conditions: Depression; Depressive Disorder, Major; Depression in Remission

Summary: objective: "decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions. the current study sought to examine the role of decentering, and other related variables, in the efficacy of mindfulness-based cognitive therapy (mbct) as compared to two active comparison conditions. method: formerly depressed individuals (n = 227), randomly assigned to mbct (n = 74), relaxation group therapy (rgt; n = 77) or treatment-as-usual (tau; n = 76), completed self-report measures of decentering and symptoms of depression at pre-, mid-, and post-treatment, and relapse was assessed at 3, 6, 9, and 12 months, post-treatment.


Eligibility criteria:
inclusion criteria: * a diagnostic and statistical manual of mental disorders (4th ed.; dsm iv-tr; american psychiatric association (apa), diagnosis of major depressive disorder (mdd) without psychotic features, in full remission; * three or more prior major depressive episodes; * age between 18 and 65 years; * cognitive reactivity (cr) or mood-activated dysfunctional beliefs score greater than or equal to eight (see assessment procedure below); * a score of less than 10 on the hamilton rating scale for depression (hrsd); * minimum of a 10 week period free of psychotropic medication other than stable dosage of antidepressant medication for a minimum of four weeks; * fluency in english; an increased cognitive reactivity score of eight points or more and, * ability to give informed consent and complete questionnaires unassisted. exclusion criteria: * a diagnosis of bipolar disorder (past or present), schizophreniform disorders, substance abuse or dependence (current or within the past six months), borderline or antisocial personality disorder, or neurocognitive disorders; * current psychotherapy or counselling more frequently than twice per month; * current practice of meditation more than once per week or yoga more than twice per week; * electroconvulsive therapy within the past six months; or * self-reported ingestion of alcohol or other psychoactive substances within the past 48 hrs.
the effect of physical activity enhancement scheme (paces) in hemodialysis patients

Conditions: Kidney Failure, Chronic; Exercise; Physical Activity; Renal Dialysis

Summary: hemodialysis is the most commonly used renal replacement therapy for end-stage renal disease (esrd) patients. at present, more than 553,000 esrd patients in china are receiving hemodialysis treatment, but the long-term survival rate is low, and the annual mortality rate is as high as 18%. this is significantly related to lower physical activity in hemodialysis patients. physical inactivity can lead to the decline of cardiopulmonary function and muscle function, the aggravation of daily life restriction and the increased risk of death. the national kidney foundation disease outcomes quality initiative (k/doqi) recommends physical activity as cornerstone of esrd rehabilitation. but hemodialysis patients are still living in a physical inactivity state. in the early stage of this study, the physical activity enhancement scheme (paces) was developed for hemodialysis patients, that is, taking spaces as the core of physical activity investigation, and encouraging patients to start to improve physical activity. the paces has been registered on the clinicaltrials.gov before (number: nct05189795). the investigators now plan to evaluate the impact of paces on physical activity of hemodialysis patients through clinical trials.


Eligibility criteria:
inclusion criteria: * adult (age≥18) with stable esrd; * receiving≥3 months hd; * receiving hd more than 5 times every two weeks; * volunteer for participating in this investigation. exclusion criteria: * are unable to do walk on one's own (severe musculoskeletal pain at rest or with minimal activity precluding walking or stationary cycling; unable to sit, stand or walk unassisted, walking devices such as cane or walker allowed); * have shortness of breath at rest or with activities of daily living (nyha class iv); * have mental disease, disturbance of consciousness and couldn't cooperate with this investigation.

Keywords: end-stage renal disease exercise physical activity hemodialysis